Related Experiment Videos
Treatment of small intestine bacterial overgrowth with rifaximin, a non-absorbable rifamycin
G R Corazza1, M Ventrucci, A Strocchi
1Department of Medical Pathology, University of Bologna, Italy.
The Journal of International Medical Research
|July 1, 1988
Abstract:
In twelve patients affected by small bowel bacterial overgrowth, diagnosed by means of the lactulose hydrogen breath test, the therapeutic efficacy of a non-absorbable derivative of rifamycin, rifaximin, was evaluated. This study showed that this drug has a satisfactory therapeutic efficacy in contaminated small bowel syndrome and, at the doses tested, is free of side-effects.